Logo image of ACB

AURORA CANNABIS INC (ACB) Stock Fundamental Analysis

NASDAQ:ACB - Nasdaq - CA05156X8504 - Common Stock - Currency: USD

4.54  +0.07 (+1.57%)

After market: 4.5762 +0.04 (+0.8%)

Fundamental Rating

4

Overall ACB gets a fundamental rating of 4 out of 10. We evaluated ACB against 195 industry peers in the Pharmaceuticals industry. The financial health of ACB is average, but there are quite some concerns on its profitability. ACB is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ACB was profitable.
In the past year ACB had a positive cash flow from operations.
In the past 5 years ACB reported 4 times negative net income.
In the past 5 years ACB reported 4 times negative operating cash flow.
ACB Yearly Net Income VS EBIT VS OCF VS FCFACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1B -2B -3B

1.2 Ratios

Looking at the Return On Assets, with a value of 0.27%, ACB belongs to the top of the industry, outperforming 82.05% of the companies in the same industry.
ACB's Return On Equity of 0.40% is amongst the best of the industry. ACB outperforms 82.56% of its industry peers.
Industry RankSector Rank
ROA 0.27%
ROE 0.4%
ROIC N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ACB Yearly ROA, ROE, ROICACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200 -250

1.3 Margins

ACB's Profit Margin of 0.66% is amongst the best of the industry. ACB outperforms 82.05% of its industry peers.
The Gross Margin of ACB (3.57%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of ACB has declined.
Industry RankSector Rank
OM N/A
PM (TTM) 0.66%
GM 3.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
ACB Yearly Profit, Operating, Gross MarginsACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACB has more shares outstanding
Compared to 5 years ago, ACB has less shares outstanding
The debt/assets ratio for ACB has been reduced compared to a year ago.
ACB Yearly Shares OutstandingACB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ACB Yearly Total Debt VS Total AssetsACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

Based on the Altman-Z score of -9.07, we must say that ACB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ACB (-9.07) is worse than 70.26% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that ACB is not too dependend on debt financing.
The Debt to Equity ratio of ACB (0.14) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -9.07
ROIC/WACCN/A
WACC8.85%
ACB Yearly LT Debt VS Equity VS FCFACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

A Current Ratio of 4.31 indicates that ACB has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.31, ACB is doing good in the industry, outperforming 65.13% of the companies in the same industry.
ACB has a Quick Ratio of 2.16. This indicates that ACB is financially healthy and has no problem in meeting its short term obligations.
ACB has a Quick ratio of 2.16. This is comparable to the rest of the industry: ACB outperforms 46.15% of its industry peers.
Industry RankSector Rank
Current Ratio 4.31
Quick Ratio 2.16
ACB Yearly Current Assets VS Current LiabilitesACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

ACB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 171.62%, which is quite impressive.
Looking at the last year, ACB shows a very strong growth in Revenue. The Revenue has grown by 26.98%.
Measured over the past years, ACB shows a small growth in Revenue. The Revenue has been growing by 6.94% on average per year.
EPS 1Y (TTM)171.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%136.24%
Revenue 1Y (TTM)26.98%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%27.88%

3.2 Future

The Earnings Per Share is expected to grow by 24.45% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 8.70% on average over the next years. This is quite good.
EPS Next Y-42.06%
EPS Next 2Y0.01%
EPS Next 3Y28.69%
EPS Next 5Y24.45%
Revenue Next Year11.5%
Revenue Next 2Y9.41%
Revenue Next 3Y8.35%
Revenue Next 5Y8.7%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ACB Yearly Revenue VS EstimatesACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
ACB Yearly EPS VS EstimatesACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 10.56, the valuation of ACB can be described as very reasonable.
89.74% of the companies in the same industry are more expensive than ACB, based on the Price/Earnings ratio.
ACB is valuated cheaply when we compare the Price/Earnings ratio to 27.45, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 18.18, the valuation of ACB can be described as rather expensive.
74.36% of the companies in the same industry are more expensive than ACB, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.90, ACB is valued at the same level.
Industry RankSector Rank
PE 10.56
Fwd PE 18.18
ACB Price Earnings VS Forward Price EarningsACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACB Per share dataACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

ACB's earnings are expected to grow with 28.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.01%
EPS Next 3Y28.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AURORA CANNABIS INC

NASDAQ:ACB (7/3/2025, 8:25:54 PM)

After market: 4.5762 +0.04 (+0.8%)

4.54

+0.07 (+1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)06-18 2025-06-18/bmo
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners19.7%
Inst Owner Change64.91%
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap249.06M
Analysts74
Price Target7.04 (55.07%)
Short Float %9.19%
Short Ratio4.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2232.55%
Min EPS beat(2)-28.95%
Max EPS beat(2)4494.06%
EPS beat(4)2
Avg EPS beat(4)1130.81%
Min EPS beat(4)-110.8%
Max EPS beat(4)4494.06%
EPS beat(8)4
Avg EPS beat(8)527.58%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.94%
Min Revenue beat(2)-3.91%
Max Revenue beat(2)13.79%
Revenue beat(4)3
Avg Revenue beat(4)7.88%
Min Revenue beat(4)-3.91%
Max Revenue beat(4)14.66%
Revenue beat(8)6
Avg Revenue beat(8)5.45%
Revenue beat(12)6
Avg Revenue beat(12)2.01%
Revenue beat(16)8
Avg Revenue beat(16)1.82%
PT rev (1m)-7.85%
PT rev (3m)-4.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.54%
Valuation
Industry RankSector Rank
PE 10.56
Fwd PE 18.18
P/S 0.99
P/FCF N/A
P/OCF 21.15
P/B 0.6
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)0.43
EY9.47%
EPS(NY)0.25
Fwd EY5.5%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)0.21
OCFY4.73%
SpS4.61
BVpS7.61
TBVpS6.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.27%
ROE 0.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 0.66%
GM 3.57%
FCFM N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score7
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.64%
Cap/Sales 5.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.31
Quick Ratio 2.16
Altman-Z -9.07
F-Score7
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)171.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%136.24%
EPS Next Y-42.06%
EPS Next 2Y0.01%
EPS Next 3Y28.69%
EPS Next 5Y24.45%
Revenue 1Y (TTM)26.98%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%27.88%
Revenue Next Year11.5%
Revenue Next 2Y9.41%
Revenue Next 3Y8.35%
Revenue Next 5Y8.7%
EBIT growth 1Y5.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year150.01%
EBIT Next 3Y37.58%
EBIT Next 5Y32.86%
FCF growth 1Y96.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y123.36%
OCF growth 3YN/A
OCF growth 5YN/A